Current therapeutic recommendations in multiple sclerosis

Journal of the Neurological Sciences

Volumn 287, Issue SUPPL. 1, 2009, Pages

  Berger, Thomas ^a  

^a Research Unit   (Austria)

Author keywords

Glatiramer acetate; Guidelines; interferon ; mitoxantrone; Multiple sclerosis; natalizumab; Treatment

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DEMYELINATION; GLIOSIS; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMYELINIZATION; TREATMENT FAILURE;

DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 72649104547     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)71299-7     Document Type: Article

References (61)

1. Achiron A., and Fredrikson S. Lessons from randomised direct comparative trials. J Neurol Sci 277 Suppl 1 (2009) S19-S24
2. Goodin D.S. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 71 (2008) S8-13
3. Rieckmann P., and Toyka K.V. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol 42 (1999) 121-127
4. Rieckmann P., Toyka K.V., Bassetti C., Beer K., Beer S., Buettner U., et al. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J Neurol 251 (2004) 1329-1339
5. Wiendl H., Toyka K.V., Rieckmann P., Gold R., Hartung H.P., and Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255 (2008) 1449-1463
6. Miller D.H., Weinshenker B.G., Filippi M., Banwell B.L., Cohen J.A., Freedman M.S., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (Houndmills, Basingstoke, England) 14 (2008) 1157-1174
7. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
8. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 (2005) 840-846
9. Lebrun C., Bensa C., Debouverie M., De Seze J., Wiertlievski S., Brochet B., et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 79 (2008) 195-198
10. Okuda D.T., Mowry E.M., Beheshtian A., Waubant E., Baranzini S.E., Goodin D.S., et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72 (2009) 800-805
11. Jarius S., Franciotta D., Bergamaschi R., Wright H., Littleton E., Palace J., et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68 (2007) 1076-1077
12. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
13. Marignier R., De Seze J., Vukusic S., Durand-Dubief F., Zephir H., Vermersch P., et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 14 (2008) 440-445
14. Paul F., Jarius S., Aktas O., Bluthner M., Bauer O., Appelhans H., et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4 (2007) e133
15. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130 (2007) 1235-1243
16. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65 (2008) 913-919
17. Wakahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., and Nakamura M. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210 (2006) 307-313
18. Rio J., Tintoré M., Nos C., Tellez N., Galan I., and Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252 (2005) 795-800
19. Sorensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362 (2003) 1184-1191
20. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
21. Deisenhammera F., Mayringer I., Harvey J., Dilitz E., Gasse T., Stadlbauer D., et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54 (2000) 2055-2060
22. Sørensen P.S., Deisenhammer F., Duda P., Hohlfeld R., Myhr K.M., Palace J., et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12 (2005) 817-827
23. Gneiss C., Tripp P., Reichartseder F., Egg R., Ehling R., Lutterotti A., et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England) 12 (2006) 731-737
24. Caon C., Din M., Ching W., Tselis A., Lisak R., and Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13 (2006) 471-474
25. Capobianco M., Sala A., Malucchi S., Caldano M., Di Sapio A., Sperli F., et al. Glatiramer acetate reduces disease activity in neutralising antibodies to IFNb positive patients. Mult Scler 13 (2007) P235
26. Carrá A., Onaha P., Luetic G., Burgos M., Crespo E., Deri N., et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 15 (2008) 386-393
27. Zwibel H.L. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 113 (2006) 378-386
28. Vallittu A.M., Peltoniemi J., Elovaara I., Kuusisto H., Farkkila M., Multanen J., et al. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 112 (2005) 234-237
29. Cadavid D., Wolansky L.J., Skurnick J., Lincoln J., Cheriyan J., Szczepanowski K., et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 72 (2009) 1976-1983
30. Mikol D.D., Barkhof F., Chang P., Coyle P.K., Jeffery D.R., Schwid S.R., et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7 (2008) 903-914
31. O'Connor P., Filippi M., Arnason B., Comi G., Cook S., Goodin D., et al. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8 (2009) 889-897
32. Comi G., Martinelli V., Rodegher M., Moiola L., Bajenaru O., Carra A., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374 (2009) 1503-1511
33. Wolinsky J.S., Narayana P.A., O'Connor P., Coyle P.K., Ford C., Johnson K., et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61 (2007) 14-24
34. Montalban X. Early treatment: PreCISe-ly what the patient needs. J Neurol Sci 287 1 (2009) S2-S6
35. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
36. Ford C.C., Johnson K.P., Lisak R.P., Panitch H.S., Shifronis G., and Wolinsky J.S. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 12 (2006) 309-320
37. Ramtahal J., Jacob A., Das K., and Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253 (2006) 1160-1164
38. Ramtahal J., and Boggild M. Glatiramer acetate following mitoxantrone induction in relapsing remitting multiple sclerosis: extended experience. Mult Scler 14 (2008) S175
39. Vollmer T., Panitch H., Bar-Or A., Dunn J., Freedman M.S., Gazda S.K., et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14 (2008) 663-670
40. Arnold D.L., Campagnolo D., Panitch H., Bar-Or A., Dunn J., Freedman M.S., et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 255 (2008) 1473-1478
41. Stüve O. Knowns and unknowns in the future of multiple sclerosis treatment. J Neurol Sci 287 1 (2009) S30-S36
42. Edan G., Comi G., Lebrun C., Brassat D., Lubetzki C., Stankoff B., et al. The French-Italian Mitoxantrone-Interferon-beta Trial: a 3-year randomised study. Mult Scler 13 Suppl 2 (2007)
43. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62 (1997) 112-118
44. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
45. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244 (1997) 153-159
46. Morrissey S.P., Le Page E., and Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 12 (2005) 74-87
47. Casetta I., Iuliano G., and Filippini G. Azathioprine for multiple sclerosis. Cochrane database of systematic reviews (Online) (2007) CD003982.
48. La Mantia L., Mascoli N., and Milanese C. Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci 28 (2007) 299-303
49. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46 (1999) 878-886
50. Meca-Lallana J.E., Rodriguez-Hilario H., Martinez-Vidal S., Saura-Lujan I., Carreton-Ballester A., Escribano-Soriano J.B., et al. [Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study]. Rev Neurol 37 (2003) 917-926
51. Fergusson D., Hutton B., Sharma M., Tinmouth A., Wilson K., Cameron D.W., et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 45 (2005) 1640-1657
52. Sorensen P.S., Fazekas F., and Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9 (2002) 557-563
53. Sorensen P.S. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegener Dis 5 (2008) 8-15
54. Achiron A., Kishner I., Sarova-Pinhas I., Raz H., Faibel M., Stern Y., et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61 (2004) 1515-1520
55. Weber M.S., Stuve O., Neuhaus O., Hartung H.P., and Zamvil S.S. Spotlight on statins. Int MS J/MS Forum 14 (2007) 93-97
56. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
57. Paul F., Waiczies S., Wuerfel J., Bellmann-Strobl J., Dorr J., Waiczies H., et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3 (2008) e1928
58. Birnbaum G., Cree B., Altafullah I., Zinser M., and Reder A.T. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71 (2008) 1390-1395
59. Anonymous. Atorvastatin (Lipitor) therapy in patients with clinically isolated syndrome (CIS) at risk for multiple sclerosis (STAYCIS). 2009 [cited; available from: http://clinicaltrials.gov/show/NCT00094172].
60. Julian L.J., Vella L., Vollmer T., Hadjimichael O., and Mohr D.C. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol 255 (2008) 1354-1360
61. Ganzinger U., Badelt C., Vass K., Strasser-Fuchs S., Fazekas F., Berger T., et al. [Health care costs of multiple sclerosis in Austria. Cross-sectional study including consideration of quality of life]. Nervenarzt 75 (2004) 1000-1006